We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+44.95%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$335M
AUM Growth
+$92.6M
Cap. Flow
-$829K
Cap. Flow %
-0.25%
Top 10 Hldgs %
98.51%
Holding
17
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$829K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$245M 73.07%
6,068,125
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$22.2M 6.61%
1,115,352
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.69B
$22.2M 6.61%
1,025,000
– –
BMEA icon
4
Biomea Fusion
BMEA
$84.6M
$11.6M 3.46%
798,757
– –
CMPS
5
Compass Pathways
CMPS
$1.53B
$8.44M 2.52%
964,500
– –
GLUE icon
6
Monte Rosa Therapeutics
GLUE
$1.4B
$8.32M 2.48%
1,472,331
– –
NUVB icon
7
Nuvation Bio
NUVB
$2.2B
$3.84M 1.14%
2,541,009
– –
SPRB
8
Spruce Biosciences
SPRB
$118M
$3.53M 1.05%
16,073
– –
PSTX
9
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$3.51M 1.05%
1,043,267
– –
MRKR icon
10
Marker Therapeutics
MRKR
$18.8M
$1.73M 0.52%
314,286
– –
ELEV
11
DELISTED
Elevation Oncology
ELEV
$1.52M 0.45%
2,834,910
– –
OKUR
12
OnKure Therapeutics
OKUR
$154M
$1.42M 0.42%
88,608
– –
TECX
13
Tectonic Therapeutic
TECX
$529M
$1.37M 0.41%
84,148
– –
ACRS icon
14
Aclaris Therapeutics
ACRS
$726M
$456K 0.14%
434,455
– –
VIRX
15
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$164K 0.05%
288,571
– –
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$51.2K 0.02%
387,653
– –
SYRE icon
17
Spyre Therapeutics
SYRE
$8.54B
– –
-67,645
Closed -$829K

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Aisling Capital Management held 17 positions worth $335M, up 38% from $243M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Aisling Capital Management's Q4 2023 filing shows 1 closed position. The largest sale was Spyre Therapeutics, an estimated $829K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management fully exited Spyre Therapeutics in Q4 2023, selling an estimated $829K.
  • Aisling Capital Management's ten largest holdings make up 99% of its $335M portfolio in Q4 2023.
  • Aisling Capital Management opened 0 new positions and closed 1 in Q4 2023.
  • Aisling Capital Management's portfolio value rose 38% quarter-over-quarter to $335M.

Based on Aisling Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.